SCHEMBL14412251

SCHEMBL14412251

O=C1NCC(CCNc2nc(NCc3ccccc3Sc3ccccc3CO)nc3ccccc23)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ TAAR1 Q96RJ0 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ ACHE P22303 8/20 0.37
▸ APP P05067 7/20 0.37
▸ RAD52 P43351 3/20 0.37
▸ CASP6 P55212 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ UBE2N P61088 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ RCE1 Q9Y256 1/20 0.36
▸ BCHE P06276 5/20 0.36
▸ NLRP3 Q96P20 1/20 0.36
▸ PGK1 P00558 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14412250 0.85 SMN1; SMN2 (0.37) SMN1; SMN2ACHEAPPRAD52MAPT
SCHEMBL14412252 0.83 APP (0.40) SMN1; SMN2ACHEAPPRAD52MAPT
SCHEMBL14412249 0.78 APP (0.39) SMN1; SMN2ACHEAPPRAD52MAPT
SCHEMBL14266760 0.76 PDE5A (0.55) SMN1; SMN2TAAR1POLBHTTRAD52
SCHEMBL14256735 0.75 TAAR1 (0.46) SMN1; SMN2TAAR1POLBHTTACHE
SCHEMBL14256668 0.75 MAPT (0.46) SMN1; SMN2TAAR1POLBHTTACHE
SCHEMBL14256654 0.74 KDM4E (0.39) SMN1; SMN2TAAR1POLBHTTACHE
SCHEMBL14256672 0.74 RAD52 (0.57) HTTACHEAPPRAD52CASP6
SCHEMBL14256444 0.73 MERTK (0.53) ACHEAPPKMT2ABCHE
SCHEMBL14412272 0.73 CXCR4 (0.52) ACHEAPPMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity ANGION BIOMEDICA CORPORATION (US) 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213319-A1 Modulators of hepatocyte growth factor/c-Met activity HGF, MET, HDGF SMN1; SMN2 3533/4885TAAR1 3310/4885POLB 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback